Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. on March 9, 2018. The filing details significant changes to the Company's executive leadership and Board of Directors, including the resignation of the CEO and two directors, and the appointment of a new CEO and a new director.

Key Financial Metrics

The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the compensation and severance package for the departing CEO, Thomas Looby:

  • Final Wages and Accrued Payments: $61,699 (less withholdings).
  • Severance: $360,500 payable over 12 months, plus a $5,000 lump sum.
  • 2017 Bonus: $117,463 lump sum.
  • 2018 Pro Rata Bonus: Contingent on operational and financial milestones.
  • Moving Expense Reimbursement: Up to $12,000.
  • Stock Options: Accelerated vesting for options that would have vested during the 12-month separation period.

Material Changes Versus Prior Period

The filing reports a complete turnover of the Company's top executive leadership and partial Board composition:

  • CEO Departure: Thomas Looby resigned as President, CEO, and Director effective March 9, 2018.
  • Board Resignations: Directors Howard Palefsky and Amy Wendell resigned effective March 9, 2018, citing differences with the majority of the Board regarding corporate strategy.
  • CEO Appointment: Jack Peurach, a current director, was appointed President and CEO effective March 9, 2018.
  • Director Election: Charles Li, Ph.D., was appointed to the Board on March 11, 2018, and assigned to the Audit Committee.

Guidance, Outlook, and Risks

Management Commentary and Transition: The Company has entered into a Separation Agreement with Mr. Looby, under which he will serve as an outside advisor to the new CEO for two months to facilitate a smooth transition. Mr. Looby has agreed to a 90-day lock-up on his Common Stock sales.

Risks and Contingencies: The resignations of Mr. Palefsky and Ms. Wendell were attributed to strategic differences, though the filing explicitly states there were no disagreements regarding operations, policies, or practices. The new CEO, Mr. Peurach, has resigned from his roles on the Compensation and Audit Committees to focus on his executive duties.

Unusual Items: The filing notes that Mr. Looby's 2018 bonus is contingent on the Board determining specific operational and financial milestones.

Important Facts for Investor Verification

  • Verify the specific "operational, financial and other milestones" required for Mr. Looby to receive his prorated 2018 bonus.
  • Confirm the total number of stock options accelerated for Mr. Looby and their current exercise price.
  • Review the strategic differences cited by the resigning directors to assess potential future governance conflicts.
  • Monitor the Company's subsequent filings for the appointment of a new Chairman of the Board, as Mr. Peurach resigned from committee chairs but the filing does not explicitly name a new Board Chair.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.